New billing code for PH test in US may help speed heart-related diagnoses
American Medical Association gives CPT code to noninvasive CorVista-PH test
Written by |
Corvista Health says a new billing code for use in the U.S., to take effect next year, will allow its noninvasive, point-of-care CorVista-PH test — used by clinicians to diagnose pulmonary hypertension (PH) — to be employed more widely, and earlier, to help identify people with heart-related conditions.
The company announced that its diagnostic test has received a Category III Current Procedural Terminology (CPT) code from the American Medical Association (AMA), which creates and manages them.
CPT codes are the labels used by doctors, hospitals, and public and private health insurance programs across the U.S. to identify medical procedures and services. Category III CPT codes are a special type set aside for new or emerging technologies, procedures, and services. They’re typically used to collect data on a new service, track how often it’s used, and lay the groundwork for future insurance reimbursement.
According to Corvista, the new code — 1104T — will become effective Jan. 1, 2027, and will support reporting for the use of the CorVista System in assessing potential PH. The new billing code will also support the system’s use for detecting coronary artery disease (CAD) and pulmonary capillary wedge pressure (PCWP), the company stated in a press release.
“Receiving a Category III CPT code from the AMA is a significant milestone for CorVista and for the broader movement toward earlier, more accessible cardiovascular diagnosis,” said Adrian Lam, president and CEO of Corvista Health, adding that “this new code strengthens the foundation for broader clinical adoption” of CorVista-PH.
In PH, pressure builds up in the pulmonary arteries, the blood vessels that carry blood through the lungs. This elevated pressure forces the heart to work harder to pump blood, which can reduce oxygen delivery to the body and, over time, lead to heart failure.
For many people with PH, a diagnosis is often delayed: Many of the condition’s symptoms, including shortness of breath, dizziness, fatigue, and chest pain or pressure, overlap with those of other heart and lung conditions.
Part of the CorVista System, the CorVista-PH test detects two types of signals from the body: patterns in the heart’s electrical activity and blood flow. The resulting data are analyzed using an artificial intelligence (AI) technique called machine learning, which employs computer algorithms trained on large patient datasets to recognize disease-associated patterns.
CorVista-PH test typically done as part of doctor visit
For patients, the appeal of this type of test is that it’s done at the point of care — meaning in a doctor’s office rather than requiring a separate visit. It’s also noninvasive and delivers results without injections, fasting, exercise, radiation, or contrast agents, which are dyes used to make internal structures more visible on imaging scans.
“CorVista was built to help physicians make more informed decisions at the initial point of care, before patients enter a long and fragmented diagnostic journey,” Lam said.
The CorVista System was cleared by the U.S. Food and Drug Administration (FDA) in 2024 to help detect PH. That clearance was supported by data from two clinical studies, IDENTIFY-PH (NCT04031989) and IDENTIFY (NCT03864081). In an analysis, the test was at least 93% accurate in detecting the condition.
The system is also cleared to help detect CAD, which affects the blood vessels that supply the heart, and is awaiting FDA clearance for PCWP. Its measurements, typically taken during an invasive procedure, estimate pressure in the heart’s upper left chamber; when elevated, it can be a sign of heart failure or other related problems.
According to Corvista Health, the technology has been evaluated in clinical trials involving more than 11,000 patients to date.
The CorVista-PH test has also received breakthrough device designation from the FDA, a status intended to accelerate the development and review of devices that show potential to improve the diagnosis of serious conditions.
In April, the company announced a partnership with the Mayo Clinic to conduct an observational study that will track patient outcomes without changing their treatment. The study will assess whether using the CorVista-PH test alongside standard diagnostic procedures can improve detection, risk stratification, and referral accuracy in people with suspected PH.
According to Nikki Troiano Gainey, the company’s chief customer officer, “cardiovascular disease diagnosis remains too slow and too fragmented.” Now, “by enabling a single office-based test to support assessment, CorVista has the potential to bring advanced cardiopulmonary insight to the initial point of care,” Gainey said.
Leave a comment
Fill in the required fields to post. Your email address will not be published.